Stockscreener 앱 받기
105.14
2.30%
-2.48
시간 외 거래:
105.14
전일 마감가:
$107.62
열려 있는:
$105.55
하루 거래량:
153.42K
Relative Volume:
1.47
시가총액:
$2.11B
수익:
$152.42M
순이익/손실:
$45.24M
주가수익비율:
41.89
EPS:
2.51
순현금흐름:
$6.97M
1주 성능:
-5.85%
1개월 성능:
-13.98%
6개월 성능:
+5.05%
1년 성능:
+43.83%
1일 변동 폭
$103.06
$106.37
1주일 범위
$103.06
$112.53
52주 변동 폭
$67.72
$129.90
리간드 파마 Stock (LGND) Company Profile
명칭
Ligand Pharmaceuticals Inc
전화
858-550-7500
주소
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
LGND을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
105.14 | 2.11B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
리간드 파마 Stock (LGND) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-03 | 개시 | Oppenheimer | Outperform |
| 2024-07-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 재개 | Stephens | Overweight |
| 2021-02-04 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-06 | 개시 | Barclays | Overweight |
| 2020-03-24 | 다운그레이드 | Argus | Buy → Hold |
| 2020-03-10 | 개시 | Guggenheim | Neutral |
| 2020-02-06 | 개시 | The Benchmark Company | Buy |
| 2019-09-19 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-03 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-06 | 재확인 | H.C. Wainwright | Buy |
| 2018-10-29 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2018-10-02 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-11 | 재확인 | Argus | Buy |
| 2018-08-17 | 개시 | Goldman | Neutral |
| 2018-08-08 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-06-21 | 개시 | Argus | Buy |
| 2017-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-05 | 재개 | H.C. Wainwright | Buy |
| 2016-10-05 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-05 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2016-03-11 | 개시 | Sidoti | Buy |
| 2016-03-03 | 개시 | H.C. Wainwright | Buy |
모두보기
리간드 파마 주식(LGND)의 최신 뉴스
PALVELLA THERAPEUTICS, INC. SEC 10-K Report - TradingView
Teacher Retirement System of Texas Boosts Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
HighTower Advisors LLC Boosts Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Raymond James Financial Inc. Makes New $2.34 Million Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Swiss National Bank Has $3.86 Million Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Charles Schwab Investment Management Inc. Increases Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand’s Second Quarter Financial Results to be Reported August 3rd - Business Wire
Victory Capital Management Inc. Buys 200 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals (NASDAQ:LGND) Rating Increased to Hold at StockNews.com - Defense World
US Bancorp DE Acquires 98 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Purchased by Atria Investments Inc - Defense World
Bank of New York Mellon Corp Sells 4,847 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Smartleaf Asset Management LLC Buys 221 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Insider Sell Alert: Octavio Espinoza Sells Shares of Ligand Phar - GuruFocus
Mutual of America Capital Management LLC Has $307,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
CFO’s Major Stock Sale Shakes Up Ligand Pharma - TipRanks
Ligand Pharmaceuticals CFO Espinoza sells $575,148 in stock By Investing.com - Investing.com Canada
Ligand Pharmaceuticals CFO Espinoza sells $575,148 in stock - Investing.com
Truist Financial Corp Lowers Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Amalgamated Bank Has $592,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
LGND: First Steps into Cell & Gene Therapy - Research Tree
Ligand CEO and CFO Heading to Miami: Key Investor Access Points for LGND Shareholders - StockTitan
Ligand to Participate in March Investor Conferences - Yahoo Finance
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of “Buy” by Brokerages - Defense World
Principal Financial Group Inc. Purchases 6,382 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals’ Earnings Call Highlights Strong Growth - TipRanks
Ligand Pharmaceuticals (NASDAQ:LGND) Trading Up 7.3%Should You Buy? - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Releases Quarterly Earnings Results - MarketBeat
Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $142 From $151, Maintains Outperform Rating - Marketscreener.com
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript - Insider Monkey
RBC Raises Price Target on Ligand Pharmaceuticals to $155 From $143, Keeps Outperform Rating - Marketscreener.com
Ligand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Ligand Pharmaceuticals Reports Strong 2024 Financial Growth - TipRanks
New York State Common Retirement Fund Boosts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Ligand: Q4 Earnings Snapshot - mySA
Ligand Pharmaceuticals' Q4 Core Adjusted Net Income, Total Revenue Rise; 2025 Guidance Set - Marketscreener.com
Ligand Pharmaceuticals Incorporated Reaffirms the Earnings Guidance for the Year 2025 - Marketscreener.com
Ligand Pharma Slips To Loss In Q4; Confirms FY25 OutlookUpdate - Nasdaq
LIGAND PHARMACEUTICAL Earnings Results: $LGND Reports Quarterly Earnings - Nasdaq
Ligand Pharmaceuticals Q4 24 Earnings Conference Call At 8:30 AM ET - Nasdaq
Ligand: Q4 Earnings Snapshot -February 27, 2025 at 07:24 am EST - Marketscreener.com
Earnings Flash (LGND) Ligand Pharmaceuticals, Posts Q4 Revenue $42.8M, vs. FactSet Est of $39.0M - Marketscreener.com
Ligand Pharmaceuticals Inc Q4 Earnings Summary - Nasdaq
Ligand Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stake Reduced by Rhumbline Advisers - Defense World
Investor Network: Ligand Pharmaceuticals Incorporated to Host Earnings Call - ACCESS Newswire
Ligand Pharmaceuticals Inc (LGND) Q4 2024: Everything You Need T - GuruFocus.com
리간드 파마 (LGND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.05%
1.79%
자본화:
|
볼륨(24시간):